<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluticasone (nasal): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluticasone (nasal): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluticasone (nasal): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9135" href="/d/html/9135.html" rel="external">see "Fluticasone (nasal): Drug information"</a> and <a class="drug drug_patient" data-topicid="11688" href="/d/html/11688.html" rel="external">see "Fluticasone (nasal): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9349460"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Flonase Allergy Relief [OTC];</li>
<li>Flonase Sensimist [OTC];</li>
<li>FT Allergy Relief 24 HR [OTC];</li>
<li>Xhance</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865433"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Fluticasone;</li>
<li>Avamys;</li>
<li>RATIO-Fluticasone [DSC];</li>
<li>TEVA-Fluticasone</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F990162"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Intranasal</span></li></ul></div>
<div class="block dop drugH1Div" id="F9349532"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Product formulations are not interchangeable; use extra caution to ensure proper salt form and dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54680997-14b0-467f-9b8c-4cb52605d7f8">Allergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic r</b>
<b>hinitis (seasonal and perennial):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Fluticasone furoate (27.5 mcg/spray) (eg, Flonase Sensimist [OTC]; Avamys [Canadian product]):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 11 years: Intranasal: Initial: 1 spray <b>per nostril</b> once daily; dose may be increased, if needed, to 2 sprays <b>per nostril</b> once daily; after improvement of symptoms, decrease dose to 1 spray <b>per nostril</b> once daily. Maximum daily dose: 2 sprays <b>per nostril</b> once daily (total daily dose: 110 mcg/<b>day</b>) (AAO-HNS [Seidman 2015]; Meltzer 2009; Zhang 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Intranasal: Initial: 2 sprays <b>per nostril</b> once daily; once symptoms are controlled, dosage may be reduced to 1 spray <b>per nostril</b> once daily. Maximum daily dose: 2 sprays <b>per nostril</b> once daily (total daily dose: 110 mcg/<b>day</b>) (AAO-HNS [Seidman 2015]; Given 2010; Han 2011; Jacobs 2009; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Fluticasone propionate (50 mcg/spray) (eg, Flonase Allergy Relief [OTC]):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 4 to 11 years: Intranasal: 1 spray <b>per nostril</b> once daily (total daily dose 100 mcg/<b>day</b>) (AAO-HNS [Seidman 2015]; Grossman 1993; Richards 1996; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Intranasal: 2 sprays <b>per nostril</b> once daily for 1 week; then may adjust to 1 or 2 sprays <b>per nostril</b> once daily. Maximum dose: 2 sprays <b>per nostril</b> once daily (total daily dose: 200 mcg/<b>day</b>) (Banov 1994; van As 1993; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonallergic r</b>
<b>hinitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Fluticasone propionate (50 mcg/spray): Children ≥4 years and Adolescents: Intranasal: Initial: 1 spray <b>per nostril</b> once daily. If response is inadequate, increase to 2 sprays <b>per nostril</b> once daily. Once symptoms are controlled, reduce dose to 1 spray <b>per nostril</b> once daily. Maximum daily dose: 2 sprays <b>per nostril</b> once daily (total daily dose: 200 mcg/<b>day</b>) (AAO-HNS [Seidman 2015]; Scadding 1995; Webb 2002; manufacturer's labeling). <b>Note:</b> For optimal effects, nasal spray should be used at regular intervals.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112160"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F51112161"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied. Use with caution in patients with severe hepatic impairment; systemic availability of fluticasone may be increased in patients with hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F9349533"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9135" href="/d/html/9135.html" rel="external">see "Fluticasone (nasal): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> For patients with mucous crusting, rinsing with saline nasal spray before fluticasone administration can remove mucous crusting and improve nasal coating (deShazo 2021). If nasal obstruction is so severe that sprays cannot penetrate, consider concomitant use of an intranasal decongestant for up to 5 days (AAAAI/ACAAI [Dykewicz 2020]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54680997-14b0-467f-9b8c-4cb52605d7f8">Allergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as monotherapy or as part of an appropriate combination regimen. Scheduled administration is more efficacious and generally recommended (AAAAI/ACAAI [Dykewicz 2017]). However, for mild or episodic symptoms, may administer as needed (deShazo 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fluticasone furoate (27.5 mcg/spray): Intranasal: </b>Initial: 2 sprays in each nostril once daily, scheduled or as needed; if symptoms are controlled after 1 week, consider reducing to 1 spray in each nostril once daily, scheduled or as needed (maximum dose: 2 sprays per nostril per day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fluticasone propionate (50 mcg/spray): Intranasal: </b>Initial: 2 sprays in each nostril once daily or 1 spray in each nostril twice daily, scheduled or as needed; if symptoms are controlled after 1 week, consider reducing to 1 spray in each nostril once daily, scheduled or as needed (maximum dose: 2 sprays per nostril per day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8080cca5-f529-4ed9-be71-539081338502">Rhinosinusitis, chronic, with or without nasal polyps</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, chronic, with or without nasal polyps:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>A 1- to 3-month course of nasal corticosteroids is part of a multimodal approach to initial treatment of chronic rhinosinusitis. Patients with refractory symptoms or significant blockage by polyps may require systemic therapies or surgical intervention (Fokkens 2020; Holbrook 2021). Also used for maintenance therapy after symptom control is achieved.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fluticasone furoate (27.5 mcg/spray) (off-label use):</b>
<b>Intranasal: </b>Initial: 2 sprays in each nostril once daily; once symptoms are controlled, consider reducing to 1 spray in each nostril once daily (maximum dose: 2 sprays per nostril per day) (Venkatesan 2016; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fluticasone propionate (50 mcg/spray) (off-label use): Intranasal: </b>Initial: 2 sprays in each nostril once daily or 1 spray in each nostril twice daily; once symptoms are controlled, consider reducing to 1 spray in each nostril once daily (maximum dose: 2 sprays per nostril per day) (Holbrook 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fluticasone propionate (93 mcg/spray):</b>
<b>Intranasal:</b> 1 spray in each nostril twice daily; some patients may require 2 sprays in each nostril twice daily (maximum dose: 2 sprays in each nostril twice daily).<b></b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonallergic rhinitis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as monotherapy or as part of an appropriate combination regimen. Administer scheduled doses on a daily basis regardless of symptoms (Lieberman 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fluticasone furoate (27.5 mcg/spray) (off-label use):</b>
<b>Intranasal:</b> Initial: 2 sprays in each nostril once daily; once symptoms are controlled, consider reducing to 1 spray in each nostril once daily (maximum dose: 2 sprays per nostril per day) (Lieberman 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Fluticasone propionate (50 mcg/spray): Intranasal:</b> Initial: 2 sprays in each nostril once daily or 1 spray in each nostril twice daily; once symptoms are controlled, consider reducing to 1 spray in each nostril once daily (maximum dose: 2 sprays per nostril per day).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991445"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988752"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use caution in moderate to severe impairment due to extensive hepatic metabolism.</p></div>
<div class="block adr drugH1Div" id="F242531"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (4% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (6% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Localized erythema (nasal mucosal and septal: 4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (1% to 3%), abdominal pain (1% to 3%), diarrhea (1% to 3%), nausea and vomiting (3% to 5%), toothache (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 3%), generalized ache or pain (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Increased intraocular pressure (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Blood in nasal mucosa (1% to 3%), bronchitis (1% to 3%), cough (4%), dry nose (1% to 3%), flu-like symptoms (1% to 3%), nasal congestion (6%), nasal mucosa ulcer (3% to 8%; includes nasal septal ulceration and nasal erosions), nasopharyngitis (8%), oropharyngeal pain (1% to 3%), pharyngitis (3% to 8%), pulmonary signs and symptoms (asthma symptoms: 7%), rhinorrhea (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophageal candidiasis, intestinal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal candidiasis, nasal septum perforation, pharyngeal candidiasis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Growth retardation</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, dysgeusia, sore throat</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, nonimmune anaphylaxis, tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell, anosmia, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, cataract (including subcapsular posterior cataract), conjunctivitis, dry eye syndrome, eye irritation, glaucoma</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dry throat, dyspnea, hoarseness, nasal discomfort, throat irritation, wheezing</p></div>
<div class="block coi drugH1Div" id="F242544"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fluticasone or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use in children &lt;4 years of age (Flonase Allergy Relief) or children &lt;2 years of age (Flonase Sensimist), for the treatment of asthma, or with current injury or surgery to nose that is not fully healed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Flonase: Untreated fungal, bacterial, or tuberculosis infections of the respiratory tract</p></div>
<div class="block war drugH1Div" id="F242529"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Pediatric patients may be more susceptible to systemic toxicity. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving ≥20 mg per day of prednisone (or equivalent) may be most susceptible. Concurrent use of ritonavir (and potentially other strong inhibitors of CYP3A4) may increase fluticasone levels and effects on HPA suppression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed wound healing: Avoid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis, angioedema, rash, contact dermatitis, hypotension, bronchospasm, and urticaria) have been reported; discontinue for severe reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and/or measles should be avoided, especially if not immunized; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: Nasal septal perforation, nasal ulceration, nasal erosion, epistaxis, and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects; discontinuation of therapy may be necessary if an infection occurs; discontinue therapy if nasal septal perforation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (accumulation may occur); monitor patients closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Use caution or avoid use in patients with tuberculosis (TB) infection (latent TB) or disease (active TB) of the respiratory tract, systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Do not use in untreated localized infection involving the nasal mucosa; concurrent antimicrobial therapy should be administered if bacterial infection of the sinuses is suspected/confirmed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in long-term users or in patients who report visual changes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use for the shortest amount of time necessary to achieve symptom relief.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Prior to use, the dose and duration of treatment should be based on the risk vs benefit for each individual patient. In general, use the smallest effective dose for the shortest duration of time to minimize adverse events. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing inhalation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Consult a health care provider before use if taking medicine for HIV infection (eg, ritonavir), steroid for asthma, allergies, or skin rash, or ketoconazole (for a fungal infection). Discontinue use and consult a health care provider if you have come in contact with someone who has chicken pox, measles, or tuberculosis, symptoms do not get better within 7 days or new symptoms occur (eg, severe facial pain, thick nasal discharge), constant whistling sound from nose, changes in vision, or severe or frequent nosebleeds. Stinging or sneezing may occur for a few seconds after use. Consult a health care provider for use longer than 2 months in pediatric patients 4 to 11 years of age; in patients ≥12 years of age, a health care provider should be contacted after 6 months of use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Symptoms of corticosteroid withdrawal (eg, joint pain, muscle pain, lassitude, depression) may occur when transferring from a systemic corticosteroid to a topical corticosteroid.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878686"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In a small pediatric study conducted over one year, no statistically significant effect on growth velocity or clinically relevant changes in bone mineral density or HPA axis function were observed in children 3 to 9 years of age receiving fluticasone propionate nasal spray (200 mcg/day; n=56) versus placebo (n=52); effects at higher doses or in susceptible pediatric patients cannot be ruled out.</p></div>
<div class="block dosfc drugH1Div" id="F21005929"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Flonase 16 g bottles contain 120 sprays each.</p>
<p style="text-indent:-2em;margin-left:2em;">Flonase Allergy Relief 9.9 mL bottles contain 60 sprays, and the 15.8 mL bottles contain 120 sprays.</p></div>
<div class="block foc drugH1Div" id="F242539"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Exhaler Suspension, Nasal, as propionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xhance: 93 mcg/actuation (16 mL) [contains benzalkonium chloride, edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flonase Sensimist: 27.5 mcg/spray (5.9 mL) [contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flonase Sensimist: 27.5 mcg/spray (5.9 mL, 6.6 mL, 9.1 mL) [alcohol free; contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal, as propionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flonase Allergy Relief: 50 mcg/actuation (9.9 mL, 11.1 mL, 15.8 mL, 18.2 mL) [contains benzalkonium chloride, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief 24 HR: 50 mcg/actuation (11.1 mL) [contains benzalkonium chloride, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/actuation (16 g, 9.9 mL, 15.8 mL)</p></div>
<div class="block geq drugH1Div" id="F9349463"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F9349541"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Exhaler Suspension</b> (Xhance Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">93 mcg/ACT (per mL): $47.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Flonase Allergy Relief Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/ACT (per mL): $1.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Flonase Sensimist Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27.5 mcg/spray (per mL): $2.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Fluticasone Propionate Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/ACT (per gram): $5.33 - $11.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865434"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avamys: 27.5 mcg/spray (10 g) [contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal, as propionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/actuation (6 g, 16 g)</p></div>
<div class="block admp drugH1Div" id="F52614074"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Intranasal: Shake well prior to each use. Blow nose to clear nostrils before each use. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Do not spray into eyes. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p>
<p style="text-indent:-2em;margin-left:2em;">Flonase: Prime pump (press 6 times until fine spray appears) prior to first use or if spray unused for ≥7 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Flonase Sensimist, Avamys [Canadian Product]: Prime pump (press 6 times until fine spray appears) when using a new bottle, if bottle unused for ≥30 days, if the cap has been left off for ≥5 days, or if the device is not working properly. Wipe spray nozzle after each use with clean, dry tissue and replace cap.</p></div>
<div class="block adm drugH1Div" id="F242541"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b> For intranasal use only; do not spray in eyes or mouth. Administer at regular intervals. Shake bottle gently before each use. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright and head tilted downward, and close off the other nostril. Do not spray directly at the septum. Breathe in through nose. While inhaling, press pump to release spray. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p>
<p style="text-indent:-2em;margin-left:4em;">Avamys [Canadian product], Flonase Sensimist: Shake bottle vigorously before using. Prime pump (press 6 times until fine spray appears) prior to first use, if spray unused for ≥30 days, or if cap left off bottle for ≥5 days. Sniff gently after each spray. Wipe spray nozzle after each use with clean, dry tissue and replace cap. Once weekly, inside of cap should be cleaned with a clean, dry tissue.</p>
<p style="text-indent:-2em;margin-left:4em;">Flonase: Prime pump (press 6 times until fine spray appears) prior to first use or if spray unused for ≥7 days. Once weekly, nasal applicator may be removed and rinsed with warm water to clean.</p>
<p style="text-indent:-2em;margin-left:4em;">Xhance: Avoid spraying directly on the septum. Prior to first use, prime pump by gently shaking and press bottle 7 times until fine mist appears; if not used for ≥7 days, re-prime pump again by shaking and releasing 2 sprays into the air. Insert nosepiece deep into one nostril and form a tight seal and then place the flexible mouthpiece into the mouth; blow into the mouthpiece, and while continuing to blow, push the bottle up to actuate the spray pump; continue to blow through the mouth, but do not inhale or exhale through the nose at the time of actuation; repeat in the other nostril for a full dose.</p></div>
<div class="block sts drugH1Div" id="F9349526"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Flonase, Flonase Allergy Relief: Store between 4°C to 30°C (39°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Flonase Sensimist: Store between 15°C to 30°C (59°F to 86°F); do not refrigerate or freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">Xhance: Store at 15°C to 25°C (59°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Avoid exposure to extreme heat, cold, or light.</p>
<p style="text-indent:-2em;margin-left:2em;">Avamys [Canadian product]: Store between 4°C to 30°C (39°F to 86°F); do not refrigerate or freeze. Store in upright position with cap on.</p></div>
<div class="block usep drugH1Div" id="F53569679"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fluticasone propionate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Prescription products: Management of nasal symptoms associated with perennial nonallergic rhinitis (50 mcg/spray: FDA approved in ages ≥4 years and adults); treatment of nasal polyps (93 mcg/spray [Xhance]: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">OTC products (eg, Flonase Allergy Relief): Relief of symptoms associated with hay fever or other upper respiratory allergies (eg, nasal congestion, runny nose, sneezing, itchy nose) (50 mcg/spray: FDA approved in ages ≥4 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fluticasone furoate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Relief of symptoms associated with hay fever or other upper respiratory allergies (eg, nasal congestion, runny nose, sneezing, itchy nose) (OTC products [eg, Flonase Sensimist]: 27.5 mcg/spray: FDA approved in ages ≥2 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Approved ages and uses for specific products may vary; consult labeling for specific information.</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal corticosteroids have also been used as an adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis, primarily in patients with a history of allergic rhinitis (IDSA [Chow 2012]) and in pediatric patients with mild obstructive sleep apnea syndrome who cannot undergo adenotonsillectomy or who still have symptoms after surgery (AAP [Marcus 2012]).</p></div>
<div class="block mst drugH1Div" id="F9349456"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Flonase may be confused with Flovent</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]</p>
<p style="text-indent:-2em;margin-left:4em;">Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively, [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9349495"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F242533"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Fluticasone (Nasal).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Nasal).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Corticosteroids (Nasal) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal corticosteroid on an esketamine dosing day should administer the nasal corticosteroid at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Fluticasone (Nasal). Management: Use of nasal fluticasone together with a strong CYP3A4 inhibitor is not recommended. Consider an alternative nasal corticosteroid, when possible.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F9349487"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy; one woman in the study was also using intranasal fluticasone (Battista 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of intranasal corticosteroids in usual doses are not associated with an increased risk of fetal malformations or preterm birth (ERS/TSANZ [Middleton 2020]). Systemic absorption of fluticasone nasal is limited. Use of intranasal fluticasone is likely acceptable for the treatment of allergic rhinitis during pregnancy (Alhussien 2018; BSACI [Scadding 2017]; ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53569673"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mucous membranes for signs of fungal infection, growth (pediatric patients), signs/symptoms of hypothalamic-pituitary-adrenal (HPA) axis suppression/adrenal insufficiency; ocular changes.</p></div>
<div class="block pha drugH1Div" id="F242527"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity</p></div>
<div class="block phk drugH1Div" id="F242543"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Maximal benefit may take several days or several months (Xhance)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Fluticasone propionate: 4.2 L/kg; Fluticasone furoate: V<sub>d,ss</sub>: 608 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 to 17 beta-carboxylic acid (negligible activity)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: &lt;2%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: Fluticasone propionate: ~8 hours (~7.8 hours [Xhance]); Fluticasone furoate: ~15 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Oral: Feces (as parent drug and metabolites); Urine (&lt;5% as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51192625"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Accumulation of fluticasone in plasma may occur in patients with hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961908"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Avamys</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Avamys</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Axotide | Flutinase | Flutinase polynex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Avamys</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Flixonase</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Flutica teva</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Flutide Nasetten</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Flix | Flixonase | Fluticasone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rontilona</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Boots allergy relief nasal | Pirinase hayfever</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Avamys</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ennhale | Floresp | Flublock</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Flunase</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Clefan</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fluticasonpropionaat A | Fluticasonpropionaat PCH | Fluticasonpropionaat ratiopharm</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Nasoflo</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fluicort</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Avamys Spray | Dalman AQ | Flixonase | Flomist | Flusort | Otri Allergy</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Nazarel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Avamys</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Avamys</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Incepcom</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Avamys</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29164323">
<a name="29164323"></a>Alhussien AH, Alhedaithy RA, Alsaleh SA. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. <i>Eur Arch Otorhinolaryngol</i>. 2018;275(2):325-333. doi:10.1007/s00405-017-4785-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/29164323/pubmed" id="29164323" target="_blank">29164323</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Avamys (fluticasone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8092559">
<a name="8092559"></a>Banov CH, Woehler TR, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. <i>Ann Allergy</i>. 1994;73(3):240-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/8092559/pubmed" id="8092559" target="_blank">8092559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27349687">
<a name="27349687"></a>Battista MC, Boutin M, Venne P, et al. Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. <i>Bioanalysis</i>. 2016 Jun 28. [Epub ahead of print]<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/27349687/pubmed" id="27349687" target="_blank">27349687</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Children's Flonase Allergy Relief (fluticasone) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; August 2021.</div>
</li>
<li>
<div class="reference">
                  Children's Flonase Allergy Relief (fluticasone) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; received September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al, “IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol.</i> 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29103802">
<a name="29103802"></a>Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. <i>Ann Allergy Asthma Immunol.</i> 2017;119(6):489-511.e41. doi:10.1016/j.anai.2017.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/29103802/pubmed" id="29103802" target="_blank">29103802</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Flonase (fluticasone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2019.</div>
</li>
<li>
<div class="reference">
                  Flonase (fluticasone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; August 2016.</div>
</li>
<li>
<div class="reference">
                  Flonase Allergy Relief (fluticasone) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; June 2021.</div>
</li>
<li>
<div class="reference">
                  Flonase Allergy Relief (fluticasone) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; received June 2020.</div>
</li>
<li>
<div class="reference">
                  Flonase Allergy Relief (fluticasone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; December 2018.</div>
</li>
<li>
<div class="reference">
                  Flonase Sensimist (fluticasone) [prescribing information]. Warren, NJ; GlaxoSmithKline; July 2016.</div>
</li>
<li>
<div class="reference">
                  Flonase Sensimist (fluticasone) [prescribing information]. Warren, NJ; GlaxoSmithKline; May 2022.</div>
</li>
<li>
<div class="reference">
                  Flonase Sensimist (fluticasone) [prescribing information]. Warren, NJ; GlaxoSmithKline; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32077450">
<a name="32077450"></a>Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. <i>Rhinology</i>. 2020;58(suppl S29):1-464. doi:10.4193/Rhin20.600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/32077450/pubmed" id="32077450" target="_blank">32077450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21144223">
<a name="21144223"></a>Given JT, Cheema AS, Dreykluft T, et al. Fluticasone furoate nasal spray is effective and well tolerated for perennial allergic rhinitis in adolescents and adults. <i>Am J Rhinol Allergy</i>. 2010;24(6):444-450. doi:10.2500/ajra.2010.24.3534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/21144223/pubmed" id="21144223" target="_blank">21144223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8414833">
<a name="8414833"></a>Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. <i>Pediatrics</i>. 1993;92(4):594-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/8414833/pubmed" id="8414833" target="_blank">8414833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21888757">
<a name="21888757"></a>Han D, Liu S, Zhang Y, et al. Efficacy and safety of fluticasone furoate nasal spray in Chinese adult and adolescent subjects with intermittent or persistent allergic rhinitis. <i>Allergy Asthma Proc</i>. 2011;32(6):472-481. doi:10.2500/aap.2011.32.3474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/21888757/pubmed" id="21888757" target="_blank">21888757</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Holbrook EH. Chronic rhinosinusitis: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19419338">
<a name="19419338"></a>Jacobs R, Martin B, Hampel F, Toler W, Ellsworth A, Philpot E. Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. <i>Curr Med Res Opin</i>. 2009;25(6):1393-1401. doi:10.1185/03007990902890512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/19419338/pubmed" id="19419338" target="_blank">19419338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lieberman.1">
<a name="Lieberman.1"></a>Lieberman PL. Chronic nonallergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926173">
<a name="22926173"></a>Marcus CL, Brooks LJ, Draper KA, et al, "Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome," <i>Pediatrics</i>, 2012, 130(3):576-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/22926173/pubmed" id="22926173" target="_blank">22926173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18680490">
<a name="18680490"></a>Meltzer EO, Lee J, Tripathy I, Lim J, Ellsworth A, Philpot E. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. <i>Pediatr Allergy Immunol</i>. 2009;20(3):279-286. doi:10.1111/j.1399-3038.2008.00773.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/18680490/pubmed" id="18680490" target="_blank">18680490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8792382">
<a name="8792382"></a>Richards DH, Milton CM. Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis. <i>Pediatr Allergy Immunol</i>. 1996;7(1):35-43. doi:10.1111/j.1399-3038.1996.tb00103.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/8792382/pubmed" id="8792382" target="_blank">8792382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856-889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7584685">
<a name="7584685"></a>Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. <i>Clin Exp Allergy</i>. 1995;25(8):737-743. doi:10.1111/j.1365-2222.1995.tb00011.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/7584685/pubmed" id="7584685" target="_blank">7584685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644617">
<a name="25644617"></a>Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(1 suppl):S1-S43. doi:10.1177/0194599814561600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/25644617/pubmed" id="25644617" target="_blank">25644617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8509578">
<a name="8509578"></a>van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. <i>J Allergy Clin Immunol</i>. 1993;91(6):1146-1154. doi:10.1016/0091-6749(93)90317-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/8509578/pubmed" id="8509578" target="_blank">8509578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26405064">
<a name="26405064"></a>Venkatesan N, Lavigne P, Lavigne F, Hamid Q. Effects of fluticasone furoate on clinical and immunological outcomes (IL-17) for patients with nasal polyposis naive to steroid treatment. <i>Ann Otol Rhinol Laryngol.</i> 2016;125(3):213-218. doi:10.1177/0003489415606449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/26405064/pubmed" id="26405064" target="_blank">26405064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11995670">
<a name="11995670"></a>Webb DR, Meltzer EO, Finn AF Jr, et al. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. <i>Ann Allergy Asthma Immunol</i>. 2002;88(4):385-390. doi:10.1016/S1081-1206(10)62369-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/11995670/pubmed" id="11995670" target="_blank">11995670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xhance.1">
<a name="Xhance.1"></a>Xhance (fluticasone propionate) [prescribing information]. Yardley, PA: OptiNose US Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xhance.1">
<a name="Xhance.1"></a>Xhance (fluticasone propionate) [prescribing information]. Yardley, PA: OptiNose US Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33007780">
<a name="33007780"></a>Zhang Y, Wei P, Chen B, et al. Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study. <i>Pediatr Res</i>. 2021;89(7):1832-1839. doi:10.1038/s41390-020-01180-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluticasone-nasal-pediatric-drug-information/abstract-text/33007780/pubmed" id="33007780" target="_blank">33007780</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15932 Version 406.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
